Aroa is unlocking regenerative healing for everybody

Aroa is a soft tissue regeneration company focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. We  make a meaningful impact for patients, surgeons and clinicians by delivering high quality, simple to use products that significantly improve healing outcomes. Aroa strives to ensure its products are widely accessible, affordable and change the standard of care for many patients.

Endoform acts as a scaffold to grow new tissue, lost or damaged through disease or injury. Cells grow into the endoderm matrix to build new tissue and re-establish a blood supply. When Endoform’s job is done, it is completely replaced by the patient’s new tissue.

Endoform allows healthcare providers to move beyond managing the symptoms to addressing the underlying healing constraints and unlocking the patient’s intrinsic capacity to heal.

Endoform technology offers superior regenerative performance at a significantly lower cost than other biologics enabling more patients to have access to the benefits of regenerative healing.

Latest news

Aroa Biosurgery to list on the ASX in $225m IPO

Auckland-based soft tissue regeneration company Aroa Biosurgery Limited (Aroa) is set to list on the Australian Securities Exchange (ASX) as part of an initial public offering (IPO) that will see it raise $45m from investors.

Continue reading

Aroa Biosurgery opens new pathway for advanced wound treatment amidst COVID-19 disruption in the United States

San Diego, U.S. Soft tissue repair company Aroa Biosurgery is stepping up to support clinicians and their patients who are battling to treat wounds amid disruption to many existing U.S. facilities for wound care due to COVID-19.

Aroa Vice President Commercial, Brad Adams says the company has opened an additional pathway for its clinicians and patients to maintain access to Endoform®, an extracellular matrix technology that is proven to help wounds heal faster.

Continue reading

COVID-19 Update – Aroa Biosurgery is well placed to maintain supply of Endoform® and Myriad™ products to clinicians and patients

Aroa Biosurgery is taking the appropriate precautions and measures amid a rapidly changing global picture for COVID-19 virus.

CEO Brian Ward said; “We extend our thoughts to everyone affected by COVID-19. Our priority is ensuring our employees, contractors and customers are safe and protected from the spread of the virus. We will continue to make any necessary changes, and monitor the potential impacts of COVID-19 on our employees, customers and overall business, daily. At this stage we are not experiencing significant disruption or impact to the underlying production and marketing operations of our business and we continue to have adequate stock levels in market.”

Continue reading